Global Parenteral Nutrition Market - Focused Insights 2024-2029

MARKET INSIGHTS

The global parenteral nutrition market was valued at USD 8.46 billion in 2023 and is expected to reach USD 13.60 billion by 2029, growing at a CAGR of 8.24% during the forecast period. The market is growing due to factors such as the increasing prevalence of chronic diseases (e.g., cancer, gastrointestinal disorders), rising malnutrition cases, and an aging population that faces nutrient absorption challenges. Advancements in parenteral nutrition formulations, customized for specific patient needs, have improved safety and efficacy, encouraging adoption.

Technological advancements and product innovations are also fueling growth in the parenteral nutrition market. Improved formulations, including lipid emulsions with fewer side effects, and the development of personalized parenteral nutrition solutions are enhancing patient outcomes and safety. Governments and healthcare organizations are increasing investments in nutritional therapy, particularly in emerging markets with a high burden of malnutrition. Coupled with a rise in healthcare awareness and infrastructure improvements, these factors are enabling broader access to parenteral nutrition therapies, driving the global market's growth trajectory.

Parenteral nutrition (PN) is a medical method of delivering essential nutrients including proteins, carbohydrates, fats, vitamins, minerals, and trace elements directly into the bloodstream through an intravenous (IV) catheter. It is used for patients of all ages, from infants to adults, who cannot eat or absorb adequate nutrients through regular or tube feeding. This sterile liquid formula helps maintain proper nutritional status by bypassing the digestive system entirely, ensuring patients receive the vital nutrients they need to support health and recovery.

RECENT VENDORS ACTIVITIES

1. In 2023, American Regent introduced Potassium Phosphates Injection USP, which functions similarly to Potassium Phosphates. This FDA-approved product provides phosphorus in intravenous fluids for children and adults who are unable to obtain sufficient phosphorus from food or feeding tubes.
2. In 2022, Otsuka Pharmaceutical Co., Ltd. received approval for ENEFLUID Injection, Japan's first peripheral parenteral nutrition solution. This innovative product combines fat and water-soluble vitamins, along with glucose, electrolytes, and amino acids, in a dual-chamber bag. The approval significantly enhanced the company's product portfolio and contributed to its market growth.
3. In 2022, Fresenius Kabi completed the acquisition of Ivenix, Inc., strengthening its position in the U.S. infusion therapy market. This acquisition created a comprehensive, industry-leading offering of premium infusion therapy products, benefiting patients, customers, and stakeholders, while expanding Fresenius Kabi's range of parenteral nutrition products.
4. In 2022, Fresenius Kabi announced that its Lipid Injectable Emulsion (ILE) would be available for pediatric patients in the U.S., including both full-term and preterm newborns. This product became the first and only four-oil lipid emulsion approved for use in parenteral nutrition across all age groups.

KEY TAKEAWAYS

1. Market Growth: The global parenteral nutrition market was valued at USD 8.46 billion in 2023 and is expected to reach USD 13.60 billion by 2029, growing at a CAGR of 8.24% during the forecast period.
2. By Product: The macronutrient segment holds the largest market share of 66%. The segmental growth is due to advancements in clinical understanding and patient-specific requirements.
3. By Nutrition: The compounded PN segment shows the highest growth of 10.33%, as they play a critical role in providing tailored nutritional solutions for patients with specific medical needs.
4. By Patient Group: The adult segment holds the largest market share due to malnutrition being a significant concern in adult populations.
5. By Indication: The short-term segment accounts for the largest market share, as short-term parenteral nutrition (PN) continues to be a critical tool in supporting patients when enteral nutrition (EN) is insufficient or contraindicated.
6. By End-User: The home care & long-term care settings segment shows the highest growth, as more patients with chronic conditions seek nutritional support at home to enhance quality of life and avoid hospital-acquired infections.
7. By Geography: North America accounted for the largest share of the global parenteral nutrition market, primarily driven by the increasing prevalence of malnutrition, particularly among hospitalized patients in the U.S.
8. Growth Factor: The global parenteral nutrition market is set to grow due to increased utilization of premixed PN formulations and growing preference for home parenteral nutrition.

MARKET TRENDS & DRIVERS

Increased Utilization of Premixed PN Formulations

The utilization of premixed parenteral nutrition (PN) formulations is on the rise, reflecting the healthcare industry’s focus on safety, efficiency, and cost-effectiveness in delivering nutritional support. Premixed PN solutions are standardized nutrient formulas that come ready for use, reducing the need for compounding or manual preparation in healthcare settings. This convenience is especially valuable in hospitals and clinics where rapid response is necessary, such as emergency or critical care departments. Premixed formulations simplify the preparation process, saving time for healthcare providers and reducing the risk of human error associated with the manual mixing of nutrients, which is critical for patient safety. One of the major drivers behind the increased adoption of premixed PN is the enhanced sterility and stability it offers. Since premixed formulations are manufactured in controlled environments, they meet rigorous quality and safety standards, minimizing the risk of contamination that can arise from in-house compounding. This sterility is particularly crucial in PN, where even slight contamination can lead to severe complications due to direct bloodstream delivery. For healthcare facilities, using premixed PN also allows for easier storage, handling, and transportation, as these formulations typically have longer shelf lives and standardized packaging, making them convenient and versatile in various care settings.

Growing Preference for Home Parenteral Nutrition (HPN)

The growing preference for Home Parenteral Nutrition (HPN) reflects a shift toward patient-centered, at-home care, offering essential nutritional support for patients with long-term needs, such as gastrointestinal disorders and malabsorption syndromes. HPN enhances comfort, flexibility, and quality of life by allowing patients to receive treatment at home, reducing hospital visits, and freeing up healthcare resources for acute care. Technological advancements, such as portable infusion pumps and remote monitoring tools, have made HPN safer and more manageable for patients and caregivers, enabling healthcare providers to oversee progress remotely. This trend is further driven by healthcare policies promoting cost-effective, patient-focused care. HPN reduces hospitalization expenses and provides a viable alternative for long-term nutritional support. Improved insurance coverage in many regions has increased its accessibility, making HPN an increasingly preferred option for both patients and healthcare systems.

Growing Prevalence of Premature Births

The increasing prevalence of premature births globally is driving the demand for specialized neonatal care, including parenteral nutrition (PN). Premature infants, born before 37 weeks of gestation, cannot often consume or absorb adequate nutrition orally or enterally due to underdeveloped gastrointestinal systems, making PN critical for their growth and development. Rising premature birth rates, particularly in regions like Sub-Saharan Africa and parts of the U.S., have highlighted the need for nutrient-rich PN solutions that support growth, brain development, and immune function during critical early life stages. To address these needs, advancements in PN formulations enriched with essential nutrients such as trace elements, fatty acids, and micronutrients have improved neonatal care quality. These innovations reduce complications like nutrient imbalances and liver disease, improving survival rates and long-term outcomes for preterm infants in neonatal intensive care units (NICUs). As premature birth rates continue to rise, the emphasis on improving PN quality and safety grows, ensuring better support for vulnerable infants.

INDUSTRY RESTRAINTS

Lack of Clinical Evidence to Support Novel Technology

A key challenge in the parenteral nutrition (PN) market is the lack of robust clinical evidence to support the efficacy and safety of some novel technologies and formulations. While advances in PN, such as new formulations, delivery systems, and innovations like automated compounding, hold potential, the absence of extensive clinical trials and long-term data limits their widespread adoption. Without sufficient clinical evidence, healthcare providers may hesitate to incorporate new technologies into patient care, preferring established methods with proven safety profiles. This can slow down the adoption of innovations that could potentially improve patient outcomes, reduce complications, or offer more personalized nutritional support. Furthermore, regulatory agencies may require more substantial evidence before approving these new technologies, delaying their availability to the market.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT

The global parenteral nutrition market by product is segmented into macronutrients, automated compounds, and micronutrients. The macronutrients segment accounted for the largest market share of 66% in 2023. In the parenteral nutrition (PN) market, macronutrients such as carbohydrates, lipids, and amino acids form the core of nutritional formulas aimed at patients with compromised digestive functions or specific nutrient needs. The demand for PN with balanced macronutrient compositions has grown with advancements in clinical understanding and patient-specific requirements. Multichamber bags (MCBs) are increasingly popular, as they contain glucose, amino acids, and lipids in pre-compounded formats, streamlining the preparation and reducing error risks in both inpatient and outpatient settings. These bags are available in dual- and tri-chamber forms, with the latter containing all three primary macronutrients, which reduces manipulation and supports safer administration. The focus on macronutrient optimization aligns with the broader trends in the PN market, which is projected to grow as clinicians and manufacturers work together to improve product safety, standardization, and personalized care options.

INSIGHTS BY NUTRITION

The global parenteral nutrition market by nutrition is categorized into RTU/standard commercial PN and compounded PN. The compounded PN segment shows prominent growth, with the fastest-growing CAGR of 10.33% during the forecast period. Compounded parenteral nutrition (PN) plays a critical role in the global parenteral nutrition market, providing tailored nutritional solutions for patients with specific medical needs. Unlike standardized PN formulas, compounded PN is custom-made, allowing healthcare providers to adjust macronutrients, micronutrients, and fluid volumes to meet individual patient requirements. This approach is especially valuable for patients with unique metabolic demands or complex health conditions, such as critically ill patients or those with organ dysfunction, who require precise nutrient management. The ability to personalize nutritional content enhances treatment efficacy, reduces the risk of nutrient imbalances, and improves overall patient outcomes, making compounded PN a growing segment within the broader PN market.

INSIGHTS BY PATIENT GROUP

The global parenteral nutrition market by patient group is segmented into adults and pediatric. The adult segment dominates and holds the largest market share in 2023. The adult population relying on parenteral nutrition (PN) is growing due to conditions requiring intravenous nutritional support, such as short bowel syndrome, pancreatitis, Crohn's disease, and enterocutaneous fistulas. Total Parenteral Nutrition (TPN) is crucial for adults unable to absorb nutrients through the gastrointestinal tract. As malnutrition linked to various health issues rises, comprehensive nutritional assessments and TPN interventions are vital for improving patient outcomes. Standardized diagnostic frameworks will further enhance the management of adult malnutrition in healthcare systems.

INSIGHTS BY INDICATION

Based on the indication, the short-term segment holds the largest share of the global parenteral nutrition market. The short-term parenteral nutrition (PN) market has evolved to address the metabolic needs of critically ill patients more effectively. Fat-based solutions, compared to glucose-heavy ones, reduce inflammation and stabilize blood sugar, suggesting they can mitigate risks like hyperglycemia. This advancement highlights the importance of tailoring PN to individual needs. Short-term PN serves as a bridge for patients requiring immediate stabilization, such as during preoperative bowel rest. However, PN's complexity demands strict oversight to prevent complications like infections and electrolyte imbalances. In lower-volume facilities, particularly U.S. hospitals, ensuring safety underscores the need for rigorous training and proper handling of formulations.

INSIGHTS BY END-USER

Based on the end-user, the home care & long-term care settings segment shows significant growth with the fastest-growing CAGR of the global parenteral nutrition market during the forecast period. This growth is driven by the rising number of patients with chronic conditions who require long-term nutritional support but prefer to avoid hospital stays to improve their quality of life and reduce infection risks. Parenteral nutrition in-home care provides a cost-effective solution, allowing patients to manage their conditions comfortably while minimizing healthcare costs. Similarly, long-term care facilities, such as nursing homes, are increasingly adopting parenteral nutrition to support an aging population with complex health needs. Elderly patients with illnesses or age-related conditions that impair nutrient absorption rely on parenteral nutrition to maintain their health.

GEOGRAPHICAL ANALYSIS

North America dominates and holds the largest market share in the global parenteral nutrition market in 2023. This growth is driven by an increasing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, and short bowel syndrome, which necessitate nutritional support through parenteral methods when patients cannot ingest food orally. The market's growth is further supported by the rising rates of chronic diseases. Approximately 60% of adults in the U.S. live with at least one chronic condition, and this figure is projected to increase significantly, leading to greater reliance on parenteral nutrition to meet dietary needs during treatment. Overall, as healthcare systems adapt to these rising demands, the parenteral nutrition market in North America is poised for significant expansion in the coming years.

APAC accounted for the second-largest share of the global parenteral nutrition market and shows the highest growth during the forecast period. The parenteral nutrition (PN) market in the Asia-Pacific (APAC) region is experiencing rapid growth, fueled by increasing chronic disease prevalence, a rising aging population, and growing awareness about malnutrition’s impact on health. Several APAC countries, including China, India, and Japan, are seeing significant investments in healthcare infrastructure, which, combined with government efforts to improve nutritional health, is accelerating the adoption of clinical nutrition solutions, particularly parenteral nutrition. Chronic diseases, such as cancer, diabetes, and gastrointestinal disorders, are prevalent across APAC.

COMPETITIVE LANDSCAPE

The global parenteral nutrition market report contains exclusive data on 26 vendors. The market is marked by intense competition, driven by the presence of several key players, including Baxter, B. Braun, Fresenius Kabi, JW Pharmaceutical, Sichuan Kelun Pharmaceutical, and Grifols. These companies hold a significant share of the market and are known for their comprehensive parenteral nutrition portfolios. They focus on innovations to improve nutrient delivery systems, increase efficiency, and enhance patient outcomes. Local and regional players are also emerging, especially in developing markets, where the need for effective nutrition management solutions is increasing. In regions such as Asia-Pacific and Latin America, these players often offer cost-effective solutions that address local needs. Moreover, emerging companies are increasingly focusing on personalized nutrition solutions, which are designed to meet the specific metabolic needs of individual patients.